December 9, 2021
Logo Engeplus

Study shows effectiveness of vaccination in reducing deaths, cases and hospitalizations due to Covid in Criciúma

A study funded by the Pan American Health Organization (PAHO/WHO) and supported by the municipality of Criciúma showed the positive effect of vaccination in reducing deaths, cases and hospitalizations due to Covid-19 in the city. The document, developed by researchers from Unesc, reveals, for example, that with the start of immunization on January 19 this year, in Criciúma, there was a sharp decrease in the emergence of new cases. According to indicators, between November and December 2020, the municipality registered 6,290 new cases per month. A year later, as the process of applying fortifying agents progressed, that number had dropped to 425.

The survey also notes that in June 2021, when the municipality reached more than 83,000 doses applied, which equates to more than 40% of the population with at least one dose and more than 10% with full immunization, the rate dropped dramatically. Of deaths from Covid-19, it rose from 95 in June to four in October.

In addition to reducing cases and deaths from the disease, the study shows the effect of vaccination on reducing hospitalizations and admissions to the intensive care unit (ICU). According to the survey, in March 2021, when 10,400 immunizations were applied from the first dose and 2,277 from the second dose, Criciúma recorded 443 hospitalizations. The scenario is completely different from October of the same year, when the city counted 50 thousand immunizations applied, between the first, second and third doses, and only 15 cases were hospitalized.

This data demonstrates the success of the vaccination campaign here in the city. In June, July and August of this year alone, we applied more than 150,000 doses of the vaccine, which is in line with the ability to mobilize our health professionals in the fight against the disease,” explained Criciúma’s Director of Health Surveillance, Samuel Bucco.

Vaccination results are also positive with regard to reducing the number of patients admitted to the intensive care unit. According to the survey, in May of this year Criciúma applied 18,218 first doses and 2,686 second doses. In the same month, she recorded 76 admissions to the intensive care unit. In October, when it counted 4,9508,000 doses applied between the first, second and third doses, there were only four admissions to the intensive care unit.

“The efficacy of vaccines in reducing new cases, deaths and hospitalizations is more than proven. Working with indicators and assessments like this gives us support,” says Criciúma’s Minister of Health, Acélio Casagrande.

About Search

The research was signed by Professors Antonio Augusto Schiffer, Fernanda de Oliveira Miller and Vanessa Iribarim Avena Miranda and took into account that Criciúma has a population of 217,311, of whom about 190,000 are part of the age groups recommended by the Ministry of Health for vaccination. .

It also analyzed the period from January 19 of this year, when vaccination began in the city, until the end of October, and it was considered that 169,306 first doses, 128,739 second doses, and 11784 third doses of the vaccine against Covid-19 were applied.

vaccination

The researchers also showed, in graphs, the evolution of vaccination against Covid-19 in Criciúma. According to the indicators, 90% of the population of 20 years and older in the city has been immunized. In some age groups, the ratio is exceeded, such as 65 to 69 years.

It is noteworthy that when working with population projections, the population may be underestimated or exaggerated, which is why, in some age groups, vaccination coverage is greater than 100%.

National Scenario

Another study published by Vicruz in October showed the high efficacy of the two main vaccines used in Brazil: AstraZeneca, produced by Vicruz itself, and Coronavac, made by the Butantan Institute. Together, the two account for 80% of the doses for Brazilians.

According to the survey, those who received two doses of AstraZeneca had a 73% protection against illness, 88% against the need for hospitalization, 89% against the need for hospitalization, and 90% against death. In the case of Coronavac, the proportions were 53%, 73%, 74% and 74%, respectively.